NYSE American-listed commercial-stage pharmaceutical company marketing ZELSUVMI for molluscum contagiosum.
At a glance
- HQ: Durham
- Sector: Biotech
- Stage: Growth
- Total raised: $50.1M
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Sourced company notes 3 topics
Notes on Pelthos Therapeutics · last checked Oct 1, 2026
Overview
Commercial-stage pharmaceutical company headquartered at 4020 Stirrup Creek Drive, Durham, and listed on NYSE American as PTHS since 2025-07-02. Formed when a Ligand Pharmaceuticals subsidiary combined with Channel Therapeutics Corporation; its EDGAR history carries the former names Channel Therapeutics and Chromocell Therapeutics. As a reporting company, its financial detail is in periodic filings.
Products
Lead product ZELSUVMI treats molluscum contagiosum and launched in July 2025, generating $7.1 million in net product revenue in its first quarter as a merged company. In November 2025 Pelthos completed the acquisition of XEPI, adding a second dermatology product.
Funding
Concurrent with the merger the company closed a $50.1 million private placement led by Murchinson Ltd., which included cancellation of roughly $18.8 million in bridge capital advanced earlier in 2025.
Listed roles
All Triangle rolesChecking listed roles…